2367 related articles for article (PubMed ID: 8157469)
1. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
Bissery MC; Nguyen CH; Bisagni E; Vrignaud P; Lavelle F
Invest New Drugs; 1993 Nov; 11(4):263-77. PubMed ID: 8157469
[TBL] [Abstract][Full Text] [Related]
2. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
3. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
4. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
6. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
[TBL] [Abstract][Full Text] [Related]
7. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
8. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
12. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity on murine tumors of a novel antitumor benzoylphenylurea derivative, HO-221.
Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
Cancer Chemother Pharmacol; 1991; 28(5):351-6. PubMed ID: 1914078
[TBL] [Abstract][Full Text] [Related]
14. Activity of batracylin (NSC-320846) against solid tumors of mice.
Mucci-LoRusso P; Polin L; Bissery MC; Valeriote F; Plowman J; Luk GD; Corbett TH
Invest New Drugs; 1989 Nov; 7(4):295-306. PubMed ID: 2557298
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
Waud WR; Leopold WR; Elliott WL; Dykes DJ; Laster WR; Temple CG; Harrison SD; Griswold DP
Cancer Res; 1990 Jun; 50(11):3239-44. PubMed ID: 2334919
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of spergualin, a novel antitumor antibiotic.
Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1986 Oct; 39(10):1461-6. PubMed ID: 3781914
[TBL] [Abstract][Full Text] [Related]
19. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
20. Antitumor spectrum of deoxyspergualin and its lack of cross-resistance to other antitumor agents.
Nishikawa K; Shibasaki C; Hiratsuka M; Arakawa M; Takahashi K; Takeuchi T
J Antibiot (Tokyo); 1991 Oct; 44(10):1101-9. PubMed ID: 1955393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
